5-Amino-1MQ

guinea pig

Also seen as: 5-Amino-1-Methylquinolinium, 5A1MQ, 5-amino

The Dose Guy’s verdict

Sep 1, 2026
2 sources

Skip it. The mechanism is genuinely interesting, an enzyme target that links fat metabolism to the NAD+ pathway, and the mouse data tells a clean story. But there is not one human trial, not one human PK measurement, not one human safety number. Vendors are selling capsules to people based entirely on what happened in fat mice. The refusal is the advice: if you want to lose weight, retatrutide and tirzepatide have massive human evidence bases and they work.

Would I take it?No, zero human data.

What it is

A small-molecule inhibitor of NNMT, nicotinamide N-methyltransferase, an enzyme that chews through NAD+ and S-adenosylmethionine in fat cells. Block NNMT and, in theory, you restore NAD+ levels in adipose tissue, suppress lipogenesis, and tilt fat cells toward burning instead of storing. It is a metabolic switch rather than an appetite signal, a completely different mechanism from the GLP-1 drugs that dominate this shelf.

The pitch writes itself, which is exactly the problem. Vendors jumped on the mouse data, skipped the part where someone tests it in a person, and started selling capsules. On this shelf 5-amino-1MQ sits next to compounds like retatrutide and tirzepatide that have moved tens of thousands of people through randomized trials. The gap is not small.

What the research shows

No human trials. Zero. Everything below is animal or in-vitro work. Read it as “interesting,” not “evidence it works in you.”

Everything published is mice and dishes. There is no human chapter to summarize.

Once-daily 5-amino-1MQ for 28 days dose-dependently limited body-weight and fat-mass gains in diet-induced obese mice, improved glucose tolerance, and attenuated liver fat.Diabetes Obes Metab 2024 · mouse study

NNMT inhibitors suppressed lipogenesis in cultured adipocytes, reduced intracellular 1-methylnicotinamide, and increased intracellular NAD+ and S-adenosyl-L-methionine.Biochem Pharmacol 2018 · cell/mouse study

No human intervention trial, pharmacokinetic study, or safety study for 5-amino-1MQ exists in the published literature.as of Aug 2026

Realistic protocols

I am not building a protocol from mouse data and vendor capsules. Vendors sell 50 to 100 mg oral capsules, typically dosed once or twice daily, and that is where the community numbers come from. Nobody knows the human bioavailability, how long it lasts in a person, or whether the dose that worked subcutaneously in mice translates to an oral dose in a person. If you run it anyway, keep the dose low, keep the run short, and log everything. But the honest advice is to wait until someone publishes a human trial, or spend the money on a compound that has already passed that bar.

Side effects

No human side-effect data exists. The mice tolerated it, for what that is worth:

anecdotalMild GI discomfort reported by some users. No pattern, no denominator, no controlled observation.

unknownHuman safety is completely uncharacterized. The NNMT pathway touches NAD+ metabolism and methylation. In cancer cell lines, NNMT inhibitors including 5-amino-1MQ reduced viability and activated apoptotic pathways. Whether that matters in a healthy person at oral doses is unknown.